GALAPAGOS NV-SPON ADR (GLPG)
US36315X1019 - ADR
Galapagos Enters Oversold Territory (GLPG)
GLPG Crosses Above Key Moving Average Level
GLPG Crosses Above Key Moving Average Level
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process.
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galapagos (NASDAQ:GLPG) just reported results for the second quarter of 2024.Ga...
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology
/PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, today announced an...
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galapagos (NASDAQ:GLPG) just reported results for the first quarter of 2024.Gal...
Galapagos is Now Oversold (GLPG)
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell...
Galapagos Becomes Oversold (GLPG)
Galapagos Enters Oversold Territory (GLPG)
RSI Alert: Galapagos (GLPG) Now Oversold
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
Galapagos Breaks Above 200-Day Moving Average - Bullish for GLPG
GLPG Makes Notable Cross Below Critical Moving Average
Galapagos enters into strategic collaboration with Thermo Fisher (NASDAQ:GLPG)
Galapagos NV enters strategic collaboration with Thermo Fisher for decentralized manufacturing of CAR-T product in San Francisco area, effective January...
Galapagos signs development deal with BridGene (NASDAQ:GLPG)
Galapagos (GLPG) has entered into a strategic collaboration deal with BridGene Biosciences, with Galapagos receiving the exclusive right to commercialize any resulting products.
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
/PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional "hard-to-drug" targets, announced today a...
Galapagos to transfer Jyseleca business to Alfasigma (NASDAQ:GLPG)
Galapagos (GLPG) Tuesday said it entered into a deal to sell its Jyseleca business to Italian pharma company Alfasigma. Per the terms, Galapagos will receive a €50 million payment upfront..
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galapagos (NASDAQ:GLPG) just reported results for the third quarter of 2023.Gal...
Oversold Conditions For Galapagos (GLPG)
Galapagos Enters Oversold Territory (GLPG)
Galapagos Breaks Above 200-Day Moving Average - Bullish for GLPG
Galapagos GAAP EPS of €0.40, revenue of €178.9M (NASDAQ:GLPG)
Galapagos press release (GLPG): Q1 GAAP EPS of €0.40.Revenue of €178.9M (+31.3% Y/Y).Current financial investments and cash and cash equivalents totaled €3,990.1 million on 31 March...